FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2046453040> ?p ?o ?g. }

• W2046453040 endingPage "e1148" @default.
• W2046453040 startingPage "e1148" @default.
• W2046453040 abstract "Background Flaxseed consumption has been shown to improve blood lipids in humans and flaxseed-derived lignan has been shown to enhance glycemic control in animals. The study aimed to investigate the effect of a flaxseed-derived lignan supplement on glycemic control, lipid profiles and insulin sensitivity in type 2 diabetic patients. Methodology/Principal Findings This was a randomized, double-blind, placebo-controlled, cross-over trial and it was conducted between April and December 2006 in Shanghai, China. Seventy-three type 2 diabetic patients with mild hypercholesterolemia were enrolled into the study. Patients were randomized to supplementation with flaxseed-derived lignan capsules (360 mg lignan per day) or placebo for 12 weeks, separated by an 8-week wash-out period. HbA1c, lipid profiles, insulin resistance index and inflammatory factors were measured. Sixty-eight completed the study and were included in the analyses. The lignan supplement significantly improved glycemic control as measured by HbA1c (-0.10±0.65 % vs. 0.09±0.52 %, P = 0.001) compared to placebo; however, no significant changes were observed in fasting glucose and insulin concentrations, insulin resistance and blood lipid profiles. Urinary excretion of lignan metabolites (enterodiol and enterolactone) was significantly higher after the lignan supplement intervention compared to baseline (14.2±18.1 vs. 1.2±2.4 µg/mL, P<0.001). Data also suggested minimal competition between lignan and isoflavones for bioavailability when measured by the excretion concentrations. Conclusions/Significance Daily lignan supplementation resulted in modest, yet statistically significant improvements in glycemic control in type 2 diabetic patients without apparently affecting fasting glucose, lipid profiles and insulin sensitivity. Further studies are needed to validate these findings and explore the efficacy of lignans on type 2 diabetes. Trial Registration ClinicalTrials.gov NCT00363233" @default.
• W2046453040 created "2016-06-24" @default.
• W2046453040 creator A5004639223 @default.
• W2046453040 creator A5017935511 @default.
• W2046453040 creator A5020997696 @default.
• W2046453040 creator A5022108508 @default.
• W2046453040 creator A5024925889 @default.
• W2046453040 creator A5027815446 @default.
• W2046453040 creator A5033822228 @default.
• W2046453040 creator A5039545694 @default.
• W2046453040 creator A5069625767 @default.
• W2046453040 creator A5077035756 @default.
• W2046453040 creator A5079942174 @default.
• W2046453040 creator A5085673920 @default.
• W2046453040 creator A5088778757 @default.
• W2046453040 date "2007-11-07" @default.
• W2046453040 modified "2023-10-03" @default.
• W2046453040 title "Effects of a Flaxseed-Derived Lignan Supplement in Type 2 Diabetic Patients: A Randomized, Double-Blind, Cross-Over Trial" @default.
• W2046453040 cites W1536341958 @default.
• W2046453040 cites W1900042135 @default.
• W2046453040 cites W1914176135 @default.
• W2046453040 cites W1971123437 @default.
• W2046453040 cites W1991367080 @default.
• W2046453040 cites W2006874875 @default.
• W2046453040 cites W2019296728 @default.
• W2046453040 cites W2025373359 @default.
• W2046453040 cites W2031484324 @default.
• W2046453040 cites W2031738476 @default.
• W2046453040 cites W2031831221 @default.
• W2046453040 cites W2040286149 @default.
• W2046453040 cites W2044813539 @default.
• W2046453040 cites W2064962253 @default.
• W2046453040 cites W2065987101 @default.
• W2046453040 cites W2079828632 @default.
• W2046453040 cites W2080359177 @default.
• W2046453040 cites W2091673371 @default.
• W2046453040 cites W2095542369 @default.
• W2046453040 cites W2100478675 @default.
• W2046453040 cites W2108268914 @default.
• W2046453040 cites W2125032405 @default.
• W2046453040 cites W2137190743 @default.
• W2046453040 cites W2144852094 @default.
• W2046453040 cites W2145213030 @default.
• W2046453040 cites W2160234571 @default.
• W2046453040 cites W2163734144 @default.
• W2046453040 cites W2163893730 @default.
• W2046453040 cites W2165767402 @default.
• W2046453040 cites W2333028705 @default.
• W2046453040 cites W4211019127 @default.
• W2046453040 cites W4235141812 @default.
• W2046453040 doi "https://doi.org/10.1371/journal.pone.0001148" @default.
• W2046453040 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2048577" @default.
• W2046453040 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17987126" @default.
• W2046453040 hasPublicationYear "2007" @default.
• W2046453040 type Work @default.
• W2046453040 sameAs 2046453040 @default.
• W2046453040 citedByCount "150" @default.
• W2046453040 countsByYear W20464530402012 @default.
• W2046453040 countsByYear W20464530402013 @default.
• W2046453040 countsByYear W20464530402014 @default.
• W2046453040 countsByYear W20464530402015 @default.
• W2046453040 countsByYear W20464530402016 @default.
• W2046453040 countsByYear W20464530402017 @default.
• W2046453040 countsByYear W20464530402018 @default.
• W2046453040 countsByYear W20464530402019 @default.
• W2046453040 countsByYear W20464530402020 @default.
• W2046453040 countsByYear W20464530402021 @default.
• W2046453040 countsByYear W20464530402022 @default.
• W2046453040 countsByYear W20464530402023 @default.
• W2046453040 crossrefType "journal-article" @default.
• W2046453040 hasAuthorship W2046453040A5004639223 @default.
• W2046453040 hasAuthorship W2046453040A5017935511 @default.
• W2046453040 hasAuthorship W2046453040A5020997696 @default.
• W2046453040 hasAuthorship W2046453040A5022108508 @default.
• W2046453040 hasAuthorship W2046453040A5024925889 @default.
• W2046453040 hasAuthorship W2046453040A5027815446 @default.
• W2046453040 hasAuthorship W2046453040A5033822228 @default.
• W2046453040 hasAuthorship W2046453040A5039545694 @default.
• W2046453040 hasAuthorship W2046453040A5069625767 @default.
• W2046453040 hasAuthorship W2046453040A5077035756 @default.
• W2046453040 hasAuthorship W2046453040A5079942174 @default.
• W2046453040 hasAuthorship W2046453040A5085673920 @default.
• W2046453040 hasAuthorship W2046453040A5088778757 @default.
• W2046453040 hasBestOaLocation W20464530401 @default.
• W2046453040 hasConcept C126322002 @default.
• W2046453040 hasConcept C134018914 @default.
• W2046453040 hasConcept C142724271 @default.
• W2046453040 hasConcept C185592680 @default.
• W2046453040 hasConcept C204787440 @default.
• W2046453040 hasConcept C27081682 @default.
• W2046453040 hasConcept C2777164284 @default.
• W2046453040 hasConcept C2777180221 @default.
• W2046453040 hasConcept C2777391703 @default.
• W2046453040 hasConcept C2777927066 @default.
• W2046453040 hasConcept C2778270713 @default.
• W2046453040 hasConcept C2779306644 @default.
• W2046453040 hasConcept C2780473172 @default.
• W2046453040 hasConcept C2781264555 @default.

• next